BB Healthcare Share Price (BBH)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
BB Healthcare	LSE:BBH	London	Ordinary Share	GB00BZCNLL95	RED ORD 1P

	Price Change	% Change	Share Price	Shares Traded	Last Trade
	+1.25p	+1.03%	122.75p	651,538	16:35:22
Bid Price		Offer Price	High Price	Low Price	Open Price
121.50p		124.00p	123.50p	123.50p	123.50p

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Health Care Equipment & Services	1.9	0.7	0.2	584.5	329.83

Related Shares
Smith & Nephew (SN.), NMC Health (NMC), Physiomics (PYC), Aortech (AOR)

BB Healthcare (BBH) Latest News (2)

BB Healthcare News

Date	Time	Source	Headline
25/5/2018	15:04	UKREG	BB Healthcare Trust PLC Issue of Equity
25/5/2018	14:04	UKREG	BB Healthcare Trust PLC Net Asset Value(s)
24/5/2018	14:00	UKREG	BB Healthcare Trust PLC Net Asset Value(s)
23/5/2018	13:35	UKREG	BB Healthcare Trust PLC Net Asset Value(s)
22/5/2018	13:36	UKREG	BB Healthcare Trust PLC Net Asset Value(s)
22/5/2018	11:43	UKREG	BB Healthcare Trust PLC Holding(s) in Company
21/5/2018	15:01	UKREG	BB Healthcare Trust PLC Issue of Equity
21/5/2018	13:34	UKREG	BB Healthcare Trust PLC Net Asset Value(s)
21/5/2018	11:40	UKREG	BB Healthcare Trust PLC Holding(s) in Company
18/5/2018	14:11	UKREG	BB Healthcare Trust PLC Issue of Equity

More BB Healthcare News

BB Healthcare Takeover Rumours

BB Healthcare (BBH) Share Charts

BB Healthcare (BBH) Discussions and Chat

BB Healthcare Forums and Chat

Date	Time	Title	Posts
11/5/2018	20:09	::: B B HEALTHCARE TRUST :::	50
12/7/2006	16:01	Biotech Holders: the last to Run?	15

Add a New Thread

BB Healthcare (BBH) Most Recent Trades

No Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type

View all BB Healthcare trades in real-time

BB Healthcare (BBH) Top Chat Posts

Date	Subject
27/5/2018 09:20	BB Healthcare Daily Update: BB Healthcare is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker BBH. The last closing price for BB Healthcare was 121.50p. BB Healthcare has a 4 week average price of 108.50p and a 12 week average price of 101.50p. The 1 year high share price is 123.75p while the 1 year low share price is currently 101.50p. There are currently 268,699,768 shares in issue and the average daily traded volume is 305,412 shares. The market capitalisation of BB Healthcare is £329,828,965.22. Read Full Thread Reply
13/8/2005 08:38	energyi: WAIT ON BIOTECHS DESPITE RECENT STRENGTH by Bruce Zaro August 12, 2005 With investor optimism toward the stock market returning, I felt it appropriate to write a follow-up to my most recent article, ¡§Semiconductors Confirming Economic Strength,¡¨ by highlighting another high-octane sector of the market. Biotechnology stocks capture investors¡¦ hopes and fears like no other group, save Internet stocks. As people search for the company that will provide the cure for cancer, AID, etc. and it¡¦s no shock that the cycle of promise and disappointment in this sector can result in a $1.13 stock that runs up to $3.50 Tuesday and settles back to $1.20 by Friday. Indeed, the biotech sector as a whole thus far in 2005 has shown a first quarter performance of negative 9.9% while the second quarter rebounded to show a 12.5% gain. Love ¡¥em and hate ¡¥em all in the same year: that¡¦s the biotech group. Because this sector can be so volatile, I believe it is possible to be a little bit late to the party and still catch significant percentage moves in individual biotech issues. Thus, I tend to hold biotech stocks in our portfolios only when they clearly show signs of sponsorship and particularly when they¡¦re exhibiting such strength from oversold levels. And since this volatile sector can provide buying opportunities and significant profit taking opportunities in short order, it is wisest for most investors to steer toward the large, liquid biotech names such as Gilead, Amgen and Genentech while avoiding the flash-in-the-pan types like Entremed and Ariad, despite their momentary allure. Further, my investment management style is firmly based on the premise that when investing, market conditions are most important in determining when to act, followed by the sector¡¦s condition and only lastly by individual stock selection. This classic ¡§top-down¡¨ approach to technical analysis is crucial since studies have shown that market and sector conditions typically account for more than 75% of a stock¡¦s movement, with only a fraction of share price movement actually coming from the company¡¦s fundamentals itself. Because I so highly value market and sector conditions when analyzing what to buy, perhaps a look at whether the Biotech sector currently makes sense is in order. While the market is currently on the offensive, from a supply and demand standpoint it is in relatively poor field position and the rally from the May lows is getting tired. Recently, there have been some early signs that the summer dog days are starting to set in. Because we reach such posture in front of the often-troubling months of September and October, I am expecting any pullback we might see in those months to provide an attractive entry point. Because the Biotech sector relative strength is strong and getting stronger, it will be one of the groups I¡¦ll have my eye on in coming weeks. As can be seen in the chart below, the sector bullish percentage recently exceeded its previous top at 50 (most recent column of Xs, which mark rising trends in Point and Figure analysis): @: http://www.financialsense.com/fsu/editorials/2005/0812.html Read Full Thread Follow Reply

Date

Subject

27/5/2018
09:20

BB Healthcare Daily Update: BB Healthcare is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker BBH. The last closing price for BB Healthcare was 121.50p.
BB Healthcare has a 4 week average price of 108.50p and a 12 week average price of 101.50p.
The 1 year high share price is 123.75p while the 1 year low share price is currently 101.50p.
There are currently 268,699,768 shares in issue and the average daily traded volume is 305,412 shares. The market capitalisation of BB Healthcare is £329,828,965.22.

Read Full Thread

13/8/2005
08:38

energyi: WAIT ON BIOTECHS DESPITE RECENT STRENGTH by Bruce Zaro August 12, 2005 With investor optimism toward the stock market returning, I felt it appropriate to write a follow-up to my most recent article, ¡§Semiconductors Confirming Economic Strength,¡¨ by highlighting another high-octane sector of the market. Biotechnology stocks capture investors¡¦ hopes and fears like no other group, save Internet stocks. As people search for the company that will provide the cure for cancer, AID, etc. and it¡¦s no shock that the cycle of promise and disappointment in this sector can result in a $1.13 stock that runs up to $3.50 Tuesday and settles back to $1.20 by Friday. Indeed, the biotech sector as a whole thus far in 2005 has shown a first quarter performance of negative 9.9% while the second quarter rebounded to show a 12.5% gain. Love ¡¥em and hate ¡¥em all in the same year: that¡¦s the biotech group. Because this sector can be so volatile, I believe it is possible to be a little bit late to the party and still catch significant percentage moves in individual biotech issues. Thus, I tend to hold biotech stocks in our portfolios only when they clearly show signs of sponsorship and particularly when they¡¦re exhibiting such strength from oversold levels. And since this volatile sector can provide buying opportunities and significant profit taking opportunities in short order, it is wisest for most investors to steer toward the large, liquid biotech names such as Gilead, Amgen and Genentech while avoiding the flash-in-the-pan types like Entremed and Ariad, despite their momentary allure. Further, my investment management style is firmly based on the premise that when investing, market conditions are most important in determining when to act, followed by the sector¡¦s condition and only lastly by individual stock selection. This classic ¡§top-down¡¨ approach to technical analysis is crucial since studies have shown that market and sector conditions typically account for more than 75% of a stock¡¦s movement, with only a fraction of share price movement actually coming from the company¡¦s fundamentals itself. Because I so highly value market and sector conditions when analyzing what to buy, perhaps a look at whether the Biotech sector currently makes sense is in order. While the market is currently on the offensive, from a supply and demand standpoint it is in relatively poor field position and the rally from the May lows is getting tired. Recently, there have been some early signs that the summer dog days are starting to set in. Because we reach such posture in front of the often-troubling months of September and October, I am expecting any pullback we might see in those months to provide an attractive entry point. Because the Biotech sector relative strength is strong and getting stronger, it will be one of the groups I¡¦ll have my eye on in coming weeks. As can be seen in the chart below, the sector bullish percentage recently exceeded its previous top at 50 (most recent column of Xs, which mark rising trends in Point and Figure analysis): @: http://www.financialsense.com/fsu/editorials/2005/0812.html

Read Full Thread

BB Healthcare share price data is direct from the London Stock Exchange

Your Recent History

LSE

GKP

Gulf Keyst..

LSE

QPP

Quindell

FTSE

UKX

FTSE 100

LSE

IOF

Iofina

GBPUSD

UK Sterlin..

Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US Finance Manila

P:41 V: D:20180527 13:52:32